WSBE(SH:600421)2021-08-27 16:00Financial Performance - The company's operating revenue for the first half of 2021 was ¥59,899,379.67, representing a 10.75% increase compared to ¥54,083,490.16 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was -¥2,976,354.84, worsening from -¥1,855,672.16 in the previous year[16]. - The net cash flow from operating activities was -¥16,889,300.46, an improvement from -¥25,662,349.65 in the same period last year[16]. - The total assets decreased by 9.97% to ¥109,298,951.30 from ¥121,397,457.22 at the end of the previous year[16]. - The net assets attributable to shareholders decreased by 6.39% to ¥33,818,390.63 from ¥36,126,365.87 at the end of the previous year[16]. - The basic earnings per share for the first half of 2021 was -¥0.015, compared to -¥0.009 in the same period last year[17]. - The company reported a net loss of ¥424,765,218.80, compared to a loss of ¥421,864,882.46 in the previous period[73]. - The comprehensive income for the current period shows a total loss of RMB 3,732,651.84, indicating a significant negative impact on the company's financial performance[92]. Revenue and Sales - The company achieved a total revenue of CNY 59.9 million in the reporting period, representing a year-on-year increase of 10.75%[22][28]. - Main business income reached CNY 57.01 million, reflecting a growth of 7.03% compared to the same period last year[24]. - The company reported a 60.58% increase in sales of products outside molds and mold tables, totaling CNY 13.06 million[24]. - The company’s total cash and cash equivalents decreased by 20,750,231.22 RMB in the first half of 2021, compared to a decrease of 18,163,735.00 RMB in the same period of 2020[84]. Assets and Liabilities - The company’s total assets at the end of the reporting period were CNY 100.87 million, with a net asset value of CNY 54.14 million[32]. - Total current assets as of June 30, 2021, amount to ¥98,879,321.60, a decrease from ¥111,862,000.57 as of December 31, 2020[67]. - Total liabilities decreased from ¥12,610,228.09 to ¥7,574,027.54, a reduction of approximately 40%[73]. - The total owner's equity at the end of the reporting period is RMB 26,233,194.91, a decrease from RMB 29,965,846.75 at the end of the previous period, reflecting a decline of approximately 12.2%[92]. Cash Flow - Cash flow from operating activities showed an improvement, with a net cash flow of CNY -16.89 million, compared to CNY -25.66 million in the previous year[28]. - The total cash inflow from financing activities was 6,000,000.00 RMB, while the cash outflow was 7,528,491.85 RMB, resulting in a net cash flow of -1,528,491.85 RMB for financing activities[84]. - The company recorded a total cash outflow of 5,961,227.70 RMB from operating activities, which is a 81.3% increase compared to the previous year's outflow of 3,284,326.45 RMB[84]. Investments and Acquisitions - The company is in the process of acquiring 80% equity of Wuxi Shunrui Biological Products Co., Ltd., with the stock suspension starting from July 5, 2021, due to this major asset restructuring[53]. - The company provided a loan of RMB 5 million to its subsidiary, with an accrued interest of RMB 25,600, totaling RMB 5.0256 million as of June 30, 2021[50]. Risks and Management - The company has highlighted potential risks in its management discussion and analysis section, urging investors to be cautious[5]. - The company has adjusted credit terms for some long-term customers to secure market share, leading to an increase in accounts receivable, which poses operational risks if not managed properly[34]. Corporate Governance - The company has not disclosed any significant litigation or arbitration matters during the reporting period, indicating a stable legal standing[44]. - The company maintains a good integrity status for itself and its controlling shareholders during the reporting period[44]. Research and Development - The company has not disclosed any significant new product developments or technological advancements during this reporting period[20]. - Research and development expenses for the first half of 2021 were RMB 2,911,125.60, up from RMB 2,656,320.26 in the first half of 2020[76]. Shareholder Information - Zhejiang Hengshun Investment Co., Ltd. holds 38,136,775 shares, accounting for 19.50% of total shares[62]. - Wuhan New Generation Technology Co., Ltd. holds 34,234,261 shares, representing 17.50% of total shares, with 34,234,261 shares pledged[62]. Accounting Policies - The company operates under the accounting standards set by the Ministry of Finance, ensuring compliance and accurate financial reporting[100]. - Financial statements are prepared based on the financial reports of the company and its subsidiaries, reflecting the overall financial position, operating results, and cash flows of the group[107].